FI
KALV

Fosun International’s KalVista Pharmaceuticals KALV Stock Holding History

Fosun International’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-72,606
Closed -$2.03M – 315
2019
Q1 		$2.03M Sell
72,606
-64,837
-47% -$1.41M 0.13% 101
2018
Q4 		$2.44M Buy
+137,443
New +$2.76M 0.15% 74

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fosun International's KALV Position: Q2 2019 in Review

Fosun International sold out of KalVista Pharmaceuticals (KALV) in Q2 2019, closing a stake of 72,606 shares — an estimated $2.03M sold.

Fosun International first reported a position in KALV in Q4 2018 and held it in 2 quarters. The position peaked at $2.44M in Q4 2018. 75 funds tracked by Wall St. Rank hold KALV as of Q2 2019.

  • Fosun International reported no remaining KalVista Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Fosun International sold 72,606 KalVista Pharmaceuticals shares in Q2 2019, an estimated $2.03M.
  • Fosun International first reported a position in KalVista Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Fosun International's KalVista Pharmaceuticals position peaked at $2.44M in Q4 2018.
  • 75 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2019.

Based on Fosun International's 13F filing for Q2 2019, filed 12 Aug 2019.